Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (11418)	11/19/2002 10:33:48 AM
From: TheBusDriver	Respond to of 14101

<<Maybe we could chip in and get RK a trained monkey with a tin cup, and she can grind organ tunes on a Bay Street corner?>> Serve her right! Might be able to talk to her then as well. Option A makes the most sense but once we get close to approval you will know it by the way the stocks starts to act. We are not there yet. Hopefully Option B will not be required. Thanks very much for the well thoughout reply. Wayne

To: axial who wrote (11418)	11/19/2002 10:49:33 AM
From: twentyfirstcenturyfox	Respond to of 14101

A brutally honest assessment - ta, Jim. ox. slightly O/T: from the opposing (if slightly more successful) camp: Nov. 15, 2002 -- The FDA and the makers of the drug Bextra, are warning about newly reported allergic reactions to a nine-month-old arthritis drug. The label for Bextra is being updated with information about these serious but rare side effects, including life-threatening skin reactions. Bextra is prescribed to treat osteoarthritis, rheumatoid arthritis, and menstrual pain. Since Bextra was introduced in March, Pharmacia, Bextra's manufacturer, has reported to the FDA serious and life-threatening skin and hypersensitivity reactions to the drug. These include cases of Stevens-Johnson syndrome, a rare and potentially deadly disorder characterized by inflammation of the mucous membranes of the mouth, throat, genitals, intestinal tract, and membrane lining the eyelids, which can lead to lesions and blisters. Other side effects were toxic epidermal necrolysis -- a condition in which skin dies and peels off much like that of a severe burn victim; erythema multiforme -- a less serious condition similar to Stevens-Johnson syndrome; and scaly skin. Bextra's label will be changed to warn about these potential side effects and to warn against anyone taking it if they are allergic to sulfa-containing products. The label will state that this drug should not be used by anyone allergic to sulfa containing products. People who experience a rash while taking the drug should stop taking it immediately and see their doctor.